NMO-IgG: A specific biomarker for neuromyelitis optica

Disease Markers

Volumn 22, Issue 4, 2006, Pages 197-206

  Weinshenker, Brian G ^a   Wingerchuk, Dean M ^b   Pittock, Sean J ^a   Lucchinetti, Claudia F ^a   Lennon, Vanda A ^a  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Autoantibody; Biomarker; Immunofluorescence; Neuromyelitis optica; Optic neuritis; Transverse myelitis

Indexed keywords

AQUAPORIN; AQUAPORIN 4; BETA INTERFERON; BIOLOGICAL MARKER; GLATIRAMER; IMMUNOGLOBULIN G;

AUTOIMMUNITY; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID ANALYSIS; CLINICAL FEATURE; CONFERENCE PAPER; DISEASE COURSE; HUMAN; IMMUNE COMPLEX DEPOSITION; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NEURITIS; PATHOGENESIS; PRIORITY JOURNAL; SPINAL CORD;

EID: 33751071376     PISSN: 02780240     EISSN: None     Source Type: Journal    
DOI: 10.1155/2006/586306     Document Type: Conference Paper

References (34)

1. D.M. Wingerchuk, W.F. Hogancamp, P.C. O'Brien and B.G. Weinshenker, The clinical course of neuromyelitis optica (Devic's syndrome), Neurology 53 (1999), 1107-1114.
2. B.A.C. Cree, D.S. Goodin and S.L. Hauser, Neuromyelitis optica [Review], Seminars in Neurology 22 (2002), 105-122.
3. D.M. Wingerchuk, Neuromyelitis Optica: Current Concepts, Frontiers in Bioscience 9 (2004), 834-840.
4. V.A. Lennon, D.M. Wingerchuk, T.J. Kryzer et al., A serum autoantibody marker of neuromyelitis optica: Distinction from multiple sclerosis, Lancet 364 (2004), 2106-2112.
5. F. Gault, De la neuromyelite optique aigue, Thesis, Lyon: 1894.
6. C. Devic, Myelite subaigue compliquee de nevrite optique, Bull Med 35 (1894), 18-30.
7. G.M. Beck, A case of diffuse myelitis associated with optic neuritis, Brain 50 (1927), 687-703.
8. J. Kira, Multiple sclerosis in the Japanese population, Lancet Neurology 2 (2003), 117-127.
9. T. Misu, K. Fujihara, I. Nakashima et al., Pure optic-spinal form of multiple sclerosis in Japan, Brain 125 (2002), 2460-2468.
10. R.N. Mandler, W. Ahmed and J.E. Dencoff, Devic's neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine, Neurology 51 (1998), 1219-1220.
11. D. McAlpine, Familial neuromyelitis optica: Its occurrence in identical twins, Brain 61 (1938), 430-448.
12. L.T. Ch'ien, M.O. Medeiros, J.J. Belluomini et al., Neuromyelitis optica (Devic's syndrome) in two sisters, Clinical Electroencephalography 13 (1982), 36-39.
13. M. Keegan and B. Weinshenker, Familial Devic's disease, Canadian Journal of Neurological Sciences. 27 (2000), S57-S58.
14. K. Yamasaki, I. Horiuchi, M. Minohara et al., HLA-DPB1* 0501-associated opticospinal multiple sclerosis: clinical, neuroimaging and immunogenetic studies, Brain 122(Pt 9) (1999), 1689-1696.
15. J.I. O'Riordan, H.L. Gallagher, A.J. Thompson et al., Clinical, CSF, and MRI findings in Devic's neuromyelitis optica, Journal of Neurology, Neurosurgery & Psychiatry. 60 (1996), 382-387.
16. S.J. Pittock, V.A. Lennon, K. Krecke et al., Brain abnormalities in patients with neuromyelitis optica, Arch Neurol 63 (2006), 390-396.
17. D.M. Wingerchuk and B.G. Weinshenker, Neuromyelitis optica - Clinical predictors of a relapsing course and survival, Neurology 60 (2003), 848-853.
18. R.N. Mandler, L.E. Davis, D.R. Jeffery and M. Kornfeld, Devic's neuromyelitis optica: a clinicopathological study of 8 patients, Ann Neurol 34 (1993), 162-168.
19. C.F. Lucchinetti, R.N. Mandler, D. McGavern et al., A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica, Brain. 125 (2002), 1450-1461.
20. C.F. Lucchinetti, W. Bruck, J. Parisi et al., Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination, Ann Neurol 47 (2000), 707-717.
21. M.K. Storch, A. Stefferl, U. Brehm et al., Autoimmunity to myelin oligodendrocyte glycoprotein in rats mimics the spectrum of multiple sclerosis pathology, Brain Pathol 8 (1998), 681-694.
22. R. Gold and C. Linington, Devic's disease: bridging the gap between laboratory and clinic, Brain 125 (2002), 1425-1427.
23. J.A. Simpson, Myasthenia gravis: A new hypothesis, Scott Med J 5 (1960), 419-436.
24. V.A. Lennon, E.H. Lambert, S. Whittingham and V. Fairbanks, Autoimmunity in the Lambert-Eaton myasthenic syndrome, Muscle & Nerve 5 (1982), S21-S25.
25. V.A. Lennon, Paraneoplastic autoantibodies: the case for a descriptive generic nomenclature, Neurology 44 (1994), 2236-2240.
26. B. Weinshenker, D. Wingerchuk, S. Vukusic et al., NMO-IgG predicts relapse following longitudinally extensive transverse myelitis, Ann Neurol 59 (2006), 566-569.
27. I. Pirko, L.K. Blauwet, T.G. Lesnick and B.G. Weinshenker, The natural history of recurrent optic neuritis, Arch Neurol 61 (2004), 1401-1405.
28. F. Bonnet, P. Mercie, P. Morlat et al., Devic's neuromyelitis optica during pregnancy in a patient with systemic lupus erythematosus, Lupus 8 (1999), 244-247.
29. A. Mochizuki, A. Hayashi, S. Hisahara and S. Shoji, Steroid-responsive Devic's variant in Sjogren's syndrome, Neurology 54 (2000), 1391-1392.
30. B.M. Keegan, A.A. Pineda, R.L. McClelland et al., Plasma exchange for severe attacks of CNS demyelination: predictors of response, Neurology 58 (2002), 143-146.
31. V.A. Lennon, T.J. Kryzer, S.J. Pittock et al., IgG marker of optic-spinal MS binds to the aquaporin 4 water channel, J Exp Med 202 (2005), 473-477.
32. J.L. Smith, J.C. Finley and V.A. Lennon, Autoantibodies in paraneoplastic cerebellar degeneration bind to cytoplasmic antigens of Purkinje cells in humans, rats and mice and are of multiple immunoglobulin classes, J. Neuroimmunol. 18 (1988), 37-48.
33. E.H. Lambert and V.A. Lennon, Selected IgG rapidly induces Lambert-Eaton myasthenic syndrome in mice: Complement independence and EMG abnormalities, Muscle & Nerve. 11 (1988), 1133-1145.
34. V.A. Lennon and G.E. Griesmann, Evidence against acetylcholine receptor having a main immunogenic region as target for autoantibodies in myasthenia gravis, Neurology 39 (1989), 1069-1076.